A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Sirona Medical Secures $40M in Series B Funding

Funding to be Used to Accelerate Ongoing Product Development, Customer Onboarding, Sales and Initiatives

What To Know

  • Principle — the view that AI’s purpose in radiology is to amplify the profession, not compete with it — and that how AI is built and designed for radiology needs to be reimagined before this goal can be achieved.
  • Sirona Medical a software company founded on a deep understanding of both the practice and business of radiology, today announced $40 million in Series B financing, bringing the total capital raised to more than $60 million.

Sirona Medical a software company founded on a deep understanding of both the practice and business of radiology, today announced $40 million in Series B financing, bringing the total capital raised to more than $60 million. The funding round was led by Great Point Ventures and joined by Rose Park Advisors and Avidity Partners, with additional participation from previous investors including 8VC and Global Founders Capital.

The funding will be used to accelerate ongoing product development, customer onboarding, and sales initiatives.

“There is a critical need for better physician workflow solutions in healthcare, particularly in radiology — the only specialty practiced entirely through software,” said Cameron Andrews, founder and CEO of Sirona Medical. “The reality is that radiology IT is fatally fragmented today, and legacy software solutions were specifically designed and rigidly built for this fragmented and siloed status quo. After decades of battling with disjointed and cumbersome IT systems, radiologists are ready for a unified, cloud-native platform — for a simpler workflow experience that puts the physician experience first. They’re ready for software that just works. With this funding, we will be able to turbocharge the adoption of our RadOS platform into radiology practices across the nation and redouble our focus on our overarching mission: amplifying the profession of radiology through software.”

Sirona’s RadOS platform unifies existing radiology IT software applications — the worklist, viewer, reporter, and AI — onto a single cloud-native platform. The unification of these applications in the cloud represents a first principles rearchitecting of the IT infrastructure that powers medical imaging. As a result, RadOS can be deployed as an overlay to practices’ existing on-premise database systems (PACS and RIS), allowing radiology practices that service multiple hospitals and health systems to combine disparate workflows and data feeds into a single unified workflow experience. RadOS enables Sirona to leverage AI in ways not previously possible and serves as the foundation for Sirona Medical’s guiding ‘intelligence amplification’ or ‘IA’ principle — the view that AI’s purpose in radiology is to amplify the profession, not compete with it — and that how AI is built and designed for radiology needs to be reimagined before this goal can be achieved.

“For the better part of a decade, AI has promised to improve the practice of radiology but failed to do so,” said Andrew Perlman, founding managing partner at GreatPoint Ventures. “Sirona is redefining how AI should be used in radiology — amplifying the profession’s impact on healthcare by building software that elevates the intelligence of physicians and ultimately, the care patients receive.”

In addition to the financial backing, Mr. Perlman will join Sirona’s Board to help guide the company’s next phase of growth.

“We believe the radiology IT market exhibits many of the hallmarks of an industry ripe for disruption,” said Chris Calder, principal at Rose Park Advisors, the firm co-founded by Clayton Christensen, author and developer of the theories of disruptive innovation. “AI companies have been unable to move from theoretical utility towards mainstream adoption because existing vendors haven’t addressed the underlying IT architecture that is inhibiting innovation. By unifying disparate systems, Sirona has created a transformative platform that will unlock new value creation possibilities and shift the current frame of competition entirely.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy